All In Biotech

Drug Trial Radar · NCT06850805

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Mar 31, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
Collaborators
Paratek Pharmaceuticals Inc
First posted
Feb 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.

Conditions

  • Chronic Rhinosinusitis Without Nasal Polyps

Interventions

  • OPN-375Drug

    OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID

  • PlaceboDrug

    Placebo solution administered via exhalation delivery system (EDS).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to the end of Week 4 in the average instantaneous CSS (evaluation of symptom severity immediately preceding the time of scoring).Time frame: 4 Weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • North Alabama ENT

    Huntsville, Alabama · Not yet recruiting

  • San Tan Allergy & Asthma

    Gilbert, Arizona · Withdrawn

  • Childrens Hospital of Los Angeles

    Los Angeles, California · Not yet recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • DaVinci Research, LLC

    Sacramento, California · Recruiting

  • Rady Childrens Hospital San Diego

    San Diego, California · Not yet recruiting

  • Breathe Clear Institute

    Torrance, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Colorado ENT & Allergy

    Colorado Springs, Colorado · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Not yet recruiting

  • Southern Illinois University School of Medicine

    Springfield, Illinois · Recruiting

  • Kentuckiana ENT

    Louisville, Kentucky · Recruiting

  • Centers for Advanced ENT Care

    Towson, Maryland · Recruiting

  • University of Missouri Medical Center

    Columbia, Missouri · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Allergy, Asthma and Clinical Research Center

    Oklahoma City, Oklahoma · Recruiting

  • Vital Prospects Clinical Research Institute

    Tulsa, Oklahoma · Recruiting

  • Charleston ENT & Allergy

    North Charleston, South Carolina · Recruiting

  • Carolina ENT Clinic/CENTRI Inc.

    Orangeburg, South Carolina · Recruiting

  • Orion Clinical Research

    Austin, Texas · Recruiting

  • STAAMP Research

    San Antonio, Texas · Recruiting

  • Alamo ENT Associates

    San Antonio, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • EVMS at Old Dominion University

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.